NY
NYXH.US Nyxoah
- Market cap
- USD 91.6M
- P/E
- -
- P/B
- 1.22x
- ROE
- -135.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NYXH.US undervalued?
Graham numberThe Graham number of Nyxoah cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nyxoah fundamental analysis
No fundamental analysis for Nyxoah yet.
Nyxoah stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Full company profileNyxoah financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nyxoah annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 69.0K | 852K | 3.08M | 4.35M | 4.52M | 10.0M | 32.3M |
| Gross Profit | -89.3K | -95.1K | -486K | 39.0K | 549K | 1.93M | 2.69M | 2.97M | 6.33M | 16.8M |
| Operating Income | -10.1M | -8.45M | -8.52M | -11.2M | -26.2M | -32.5M | -45.1M | -58.8M | -82.9M | -88.2M |
| EBITDA | -8.65M | -8.49M | -8.28M | -10.6M | -22.6M | -27.9M | -42.1M | -51.8M | -82.9M | -62.3M |
| Net Income | -10.4M | -9.08M | -8.45M | -12.2M | -27.6M | -31.2M | -43.2M | -59.2M | -90.1M | -92.3M |
| EPS | -0.50 | -0.43 | -0.39 | -0.68 | -1.16 | -1.21 | -1.55 | -1.81 | -2.36 | -0.91 |
| Balance Sheet | ||||||||||
| Total Assets | 11.1M | 18.0M | 17.1M | 140M | 171M | 146M | 124M | 158M | 118M | 149M |
| Total Liabilities | 6.62M | 7.53M | 14.4M | 20.7M | 22.2M | 25.7M | 26.1M | 45.2M | 69.3M | 80.8M |
| Shareholders' Equity | 4.53M | 10.5M | 2.65M | 119M | 149M | 120M | 98.0M | 113M | 49.1M | 68.0M |
| Cash & Short-term Investments | 10.1M | 16.8M | 6.57M | 113M | 136M | 94.9M | 57.7M | 85.6M | 48.0M | 77.1M |
| Total Debt | 5.26M | 5.82M | 9.65M | 14.1M | 11.7M | 11.9M | 12.7M | 22.7M | 42.1M | 53.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -8.29M | -8.14M | -5.93M | -6.86M | -25.3M | -28.8M | -44.8M | -49.2M | -67.5M | -79.0M |
| Capital Expenditure | 91.0K | 77.0K | 5.79M | 10.7M | 11.8M | 16.3M | 11.0M | 6.07M | 805K | 3.27M |
| Free Cash Flow | -8.38M | -8.22M | -11.7M | -17.5M | -37.2M | -45.1M | -55.7M | -55.3M | -68.3M | -82.2M |
| Ratios | ||||||||||
| ROE | -229.1% | -86.8% | -319.0% | -10.3% | -18.6% | -26.0% | -44.1% | -52.3% | -183.4% | -135.8% |
| ROA | -93.1% | -50.5% | -49.6% | -8.8% | -16.2% | -21.4% | -34.8% | -37.4% | -76.1% | -62.1% |
| Net Profit Margin | - | - | - | -17,746.4% | -3,241.7% | -1,012.5% | -993.8% | -1,310.2% | -899.1% | -285.9% |
| Debt to Equity | 1.16x | 0.56x | 3.64x | 0.12x | 0.08x | 0.10x | 0.13x | 0.20x | 0.86x | 0.79x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nyxoah dividends
Nyxoah has not paid dividends in the last 9 fiscal years.
Who owns Nyxoah
- Insiders 33.27%
- Institutions 30.39%
- Public & others 36.34%
- Shares outstanding 102M
- Free float 52.6M
Top funds holding NYXH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Econopolis Belgian Champions A EUR Dis | 1.00M | 0.98% | 0.00% | Jul 2026 |
| AXAWF Eurp Ex-UK Mccp F Cap EUR | 900K | 0.88% | +55.76% | Jul 2026 |
| Belfius Equities Bel=Go C Cap | 660K | 0.65% | +523.64% | Jun 2026 |
| Aesculape SRI IC | 425K | 0.42% | +41.20% | Jun 2026 |
| apo Medical Opportunities R | 291K | 0.29% | -17.67% | Sep 2026 |
| TEQ - Disruptive Technologies - I-II | 220K | 0.22% | -36.10% | Sep 2026 |
| BNP Paribas Belgium Equity Cl EUR Acc | 184K | 0.18% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Term Trust | 112K | 0.11% | 0.00% | Jun 2026 |
| GVC Gaesco T.F.T. FI | 85.0K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 69.1K | 0.07% | 0.00% | Aug 2026 |
| Deutsche Postbank Europafonds Plus | 50.0K | 0.05% | +42.86% | Aug 2026 |
| BSO Euro Santé I | 30.0K | 0.03% | 0.00% | Oct 2026 |
| Pareturn GVC Gaesco Euro SC Eqty Fd U | 30.0K | 0.03% | 0.00% | May 2026 |
| Pareturn GVC Gaesco Absolute Return U | 30.0K | 0.03% | 0.00% | May 2026 |
| TEQ - Small & Mid Cap Tech I-II | 24.7K | 0.02% | -37.95% | Sep 2026 |
| TEQ- Disruptive Tech In I-III | 18.3K | 0.02% | -49.41% | Sep 2026 |
| AXA Pension 2033-2035 I | 16.9K | 0.02% | +52.81% | Jul 2026 |
| AXA Pension 2030-2032 I | 7.28K | 0.01% | +55.37% | Jul 2026 |
| AXA Pension Long Terme I | 6.42K | 0.01% | -57.47% | Jun 2026 |
| AXA Pension 2039-2041 I | 4.52K | 0.00% | -54.21% | Jun 2026 |
Nyxoah company profile
- Company name
- Nyxoah
- Ticker
- NYXH.US
- ISIN
- BE0974358906
- Exchange
- USA Stocks
- Listed since
- Jul 2, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 153
- Fiscal year end
- December
- Address
- Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium, 1435
- Phone
- 32 1 045 90 75
- Website
- nyxoah.com
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah management
10- Mr. Robert Taub MBACo-Founder & Chairman · born 1947
- Mr. Bruno OnkelinxChief Technical Officer · born 1972
- Mr. Liam J. KellyChief Executive Officer · born 1967
- Mr. Loic MoreauPresident of International & Interim CFO · born 1980
- Mr. Jeyakumar SubbaroyanChief Science Officer
- Mr. Remi RenardHead of Investor Relations & Corporate Communication
- Ms. An MoonenGeneral Counsel
- Dr. Maurits S. BoonChief Medical Officer
- Mr. Scott HolstineChief Commercial Officer · born 1971
- Ms. Ashlea MittelstaedtChief Strategy Officer